Microsoft Excel LibreOffice Calc

Bristol-Myers Squibb Co. (BMY)

Common Stock Valuation Ratios (Price Multiples)
Quarterly Data

Beginner level

Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).

Historical Valuation Ratios (Summary)

Bristol-Myers Squibb Co., historical price multiples (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Price to earnings (P/E) 16.53 11.97 14.51 16.81 56.09 251.38 92.56 103.55 23.59 19.40 18.96 20.56 25.80 43.47 76.64 64.22 62.78 63.57 47.75 49.80 — — —
Price to operating profit (P/OP) 13.50 10.89 13.68 16.16 19.56 27.48 23.10 28.87 24.60 20.23 19.09 19.79 24.47 43.34 64.30 53.18 41.11 40.96 36.31 38.52 — — —
Price to sales (P/S) 3.87 3.11 3.21 3.67 3.64 4.38 4.04 5.02 4.85 4.40 4.59 4.72 4.70 7.08 7.13 6.07 6.74 6.95 6.68 6.28 — — —
Price to book value (P/BV) 5.30 4.63 4.91 5.89 5.89 7.67 6.65 8.88 6.75 6.05 6.36 5.66 5.56 8.36 8.38 7.04 7.39 7.52 6.92 6.72 5.87 5.35 5.28

Based on: 10-Q (filing date: 2019-10-31), 10-Q (filing date: 2019-07-25), 10-Q (filing date: 2019-04-25), 10-K (filing date: 2019-02-25), 10-Q (filing date: 2018-10-25), 10-Q (filing date: 2018-07-26), 10-Q (filing date: 2018-04-26), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-26), 10-Q (filing date: 2017-07-27), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-21), 10-Q (filing date: 2016-10-27), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-04-28), 10-K (filing date: 2016-02-12), 10-Q (filing date: 2015-10-27), 10-Q (filing date: 2015-07-23), 10-Q (filing date: 2015-04-28), 10-K (filing date: 2015-02-13), 10-Q (filing date: 2014-10-24), 10-Q (filing date: 2014-07-24), 10-Q (filing date: 2014-04-29).

Valuation ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. Bristol-Myers Squibb Co.’s P/E ratio decreased from Q1 2019 to Q2 2019 but then increased from Q2 2019 to Q3 2019 exceeding Q1 2019 level.
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. Bristol-Myers Squibb Co.’s P/OP ratio decreased from Q1 2019 to Q2 2019 but then increased from Q2 2019 to Q3 2019 not reaching Q1 2019 level.
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. Bristol-Myers Squibb Co.’s P/S ratio decreased from Q1 2019 to Q2 2019 but then increased from Q2 2019 to Q3 2019 exceeding Q1 2019 level.
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company’s required rate of return and its actual rate of return. Bristol-Myers Squibb Co.’s P/BV ratio decreased from Q1 2019 to Q2 2019 but then increased from Q2 2019 to Q3 2019 exceeding Q1 2019 level.

Price to Earnings (P/E)

Bristol-Myers Squibb Co., historical P/E calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
No. shares of common stock outstanding1 1,629,284,798 1,635,766,530 1,635,705,782 1,632,675,877 1,632,198,774 1,631,876,909 1,634,538,458 1,632,582,502 1,636,699,696 1,639,926,446 1,647,434,458 1,672,715,340 1,671,229,946 1,670,858,535 1,669,307,273 1,669,459,090 1,668,286,317 1,667,502,766 1,666,974,545 1,662,118,446 1,658,776,491 1,657,904,666 1,657,176,162
Selected Financial Data (US$)
Net earnings (loss) attributable to BMS (in millions) 1,353  1,432  1,710  1,160  1,901  373  1,486  (2,328) 845  916  1,574  894  1,202  1,166  1,195  (197) 706  (130) 1,186  13  721  333  937 
Earnings per share (EPS)2 3.47 3.79 3.14 3.01 0.88 0.23 0.56 0.62 2.58 2.80 2.94 2.66 2.01 1.72 0.94 0.94 1.06 1.07 1.35 1.21 0.00 0.00 0.00
Share price1, 3 57.37 45.40 45.64 50.65 49.21 57.92 52.04 63.87 60.95 54.24 55.67 54.78 51.96 74.66 72.26 60.20 66.80 68.24 64.54 60.04 53.63 49.46 49.32
Valuation Ratio
P/E ratio4 16.53 11.97 14.51 16.81 56.09 251.38 92.56 103.55 23.59 19.40 18.96 20.56 25.80 43.47 76.64 64.22 62.78 63.57 47.75 49.80 — — —
Benchmarks
P/E Ratio, Competitors5
Abbott Laboratories 44.92 53.17 52.98 56.47 136.66 122.73 213.07 220.29 45.00 73.04 50.48 55.16 41.28 29.01 22.87 12.83 14.78 16.66 16.49 31.30 — — —
AbbVie Inc. 37.29 23.42 21.71 20.60 17.29 22.09 24.91 35.47 22.56 17.16 16.90 16.54 15.75 18.94 18.46 17.01 37.22 54.50 57.23 55.08 — — —
Allergan PLC — — — — 24.13 — — — — 6.83 6.75 5.60 5.20 23.71 20.21 31.94 32.56 — — — — — —
Amgen Inc. 15.53 14.06 13.30 14.01 55.79 52.69 52.13 64.06 15.67 15.70 15.16 16.03 14.24 17.32 16.55 15.95 19.03 23.01 21.63 22.96 — — —
Biogen Inc. 9.43 8.40 9.32 14.79 19.99 25.30 18.66 28.83 19.16 18.17 17.49 15.41 16.60 16.21 16.57 16.67 17.12 20.22 28.83 31.27 — — —
Eli Lilly & Co. 13.31 13.84 18.38 39.13 249.24 — 79.88 — 41.51 37.39 41.29 32.39 33.66 37.12 35.95 33.35 38.32 45.51 36.38 33.06 — — —
Gilead Sciences Inc. 30.72 13.61 14.26 15.26 57.34 45.72 24.66 22.75 8.24 7.85 6.92 6.83 6.47 6.49 6.50 6.75 9.29 11.58 10.74 12.85 — — —
Johnson & Johnson 24.03 21.50 25.68 23.74 243.48 256.64 271.47 268.10 23.75 21.91 20.12 20.08 19.64 22.55 20.29 18.80 19.00 17.23 17.45 17.15 — — —
Merck & Co. Inc. 22.67 23.07 23.97 33.46 56.97 132.14 96.71 61.63 53.20 33.41 39.83 46.14 30.16 33.87 32.46 31.64 14.26 16.71 15.25 13.94 — — —
Pfizer Inc. 12.60 16.12 19.69 21.58 10.64 10.66 9.43 9.99 21.39 23.88 27.02 28.10 32.43 30.28 26.41 26.37 25.22 24.38 22.52 23.03 — — —
Regeneron Pharmaceuticals Inc. 17.03 15.94 14.56 18.17 21.53 26.96 22.09 28.99 34.90 43.35 47.93 42.64 45.15 61.42 53.53 60.50 99.27 130.79 134.94 118.44 — — —
Vertex Pharmaceuticals Inc. 23.44 20.80 20.51 22.59 65.41 108.21 175.96 155.08 193.19 149.56 166.15 — — — — — — — — — — — —
Zoetis Inc. 39.46 42.08 35.57 28.68 38.90 39.51 39.53 44.09 35.00 33.42 33.79 31.63 35.08 39.58 62.14 62.14 51.10 57.35 38.41 39.59 — — —

Based on: 10-Q (filing date: 2019-10-31), 10-Q (filing date: 2019-07-25), 10-Q (filing date: 2019-04-25), 10-K (filing date: 2019-02-25), 10-Q (filing date: 2018-10-25), 10-Q (filing date: 2018-07-26), 10-Q (filing date: 2018-04-26), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-26), 10-Q (filing date: 2017-07-27), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-21), 10-Q (filing date: 2016-10-27), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-04-28), 10-K (filing date: 2016-02-12), 10-Q (filing date: 2015-10-27), 10-Q (filing date: 2015-07-23), 10-Q (filing date: 2015-04-28), 10-K (filing date: 2015-02-13), 10-Q (filing date: 2014-10-24), 10-Q (filing date: 2014-07-24), 10-Q (filing date: 2014-04-29).

1 Data adjusted for splits and stock dividends.

2 Q3 2019 Calculation
EPS = (Net earnings (loss) attributable to BMSQ3 2019 + Net earnings (loss) attributable to BMSQ2 2019 + Net earnings (loss) attributable to BMSQ1 2019 + Net earnings (loss) attributable to BMSQ4 2018) ÷ No. shares of common stock outstanding
= (1,353,000,000 + 1,432,000,000 + 1,710,000,000 + 1,160,000,000) ÷ 1,629,284,798 = 3.47

3 Closing price as at the filing date of Bristol-Myers Squibb Co.’s Quarterly or Annual Report.

4 Q3 2019 Calculation
P/E ratio = Share price ÷ EPS
= 57.37 ÷ 3.47 = 16.53

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. Bristol-Myers Squibb Co.’s P/E ratio decreased from Q1 2019 to Q2 2019 but then increased from Q2 2019 to Q3 2019 exceeding Q1 2019 level.

Price to Operating Profit (P/OP)

Bristol-Myers Squibb Co., historical P/OP calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
No. shares of common stock outstanding1 1,629,284,798 1,635,766,530 1,635,705,782 1,632,675,877 1,632,198,774 1,631,876,909 1,634,538,458 1,632,582,502 1,636,699,696 1,639,926,446 1,647,434,458 1,672,715,340 1,671,229,946 1,670,858,535 1,669,307,273 1,669,459,090 1,668,286,317 1,667,502,766 1,666,974,545 1,662,118,446 1,658,776,491 1,657,904,666 1,657,176,162
Selected Financial Data (US$)
Operating income (in millions) 1,760  1,877  1,719  1,567  1,659  513  1,379  556  992  756  1,308  999  1,335  1,161  1,135  (82) 664  159  1,149  739  731  344  777 
Operating profit per share2 4.25 4.17 3.34 3.13 2.52 2.11 2.25 2.21 2.48 2.68 2.92 2.77 2.12 1.72 1.12 1.13 1.63 1.67 1.78 1.56 0.00 0.00 0.00
Share price1, 3 57.37 45.40 45.64 50.65 49.21 57.92 52.04 63.87 60.95 54.24 55.67 54.78 51.96 74.66 72.26 60.20 66.80 68.24 64.54 60.04 53.63 49.46 49.32
Valuation Ratio
P/OP ratio4 13.50 10.89 13.68 16.16 19.56 27.48 23.10 28.87 24.60 20.23 19.09 19.79 24.47 43.34 64.30 53.18 41.11 40.96 36.31 38.52 — — —
Benchmarks
P/OP Ratio, Competitors5
Abbott Laboratories 34.32 37.50 36.74 36.64 38.12 38.00 39.99 60.88 47.72 41.32 30.85 24.25 18.51 23.04 20.13 19.80 23.39 26.00 24.36 27.50 — — —
AbbVie Inc. 18.43 13.53 17.93 18.35 12.32 14.01 15.78 19.63 14.77 11.57 11.19 10.49 10.48 12.51 12.44 11.61 20.93 27.81 27.74 28.64 — — —
Allergan PLC — — — — — — — — — — — — — — — — — — — — — — —
Amgen Inc. 12.52 11.35 10.73 11.46 12.13 12.16 11.45 12.71 12.55 12.46 11.99 12.64 11.56 14.06 13.50 13.07 15.51 19.05 18.03 19.13 — — —
Biogen Inc. 7.58 6.74 7.43 11.13 10.78 12.80 9.45 13.70 14.01 13.19 12.69 11.08 11.87 11.51 11.89 12.09 12.62 15.13 21.38 23.10 — — —
Eli Lilly & Co. 23.37 23.99 38.43 33.99 37.45 47.62 25.86 39.61 33.07 29.23 32.37 25.63 27.59 30.51 28.95 29.86 33.90 41.35 33.94 29.71 — — —
Gilead Sciences Inc. 19.07 9.61 10.14 10.15 9.74 9.58 6.83 7.45 6.02 5.82 5.22 5.23 5.08 5.20 5.25 5.50 7.51 9.26 8.67 10.19 — — —
Johnson & Johnson 17.23 19.08 20.36 18.34 20.42 18.93 18.18 18.94 18.71 17.29 15.95 16.09 16.59 18.63 17.98 16.50 14.96 14.14 13.43 13.36 — — —
Merck & Co. Inc. 17.97 18.21 19.17 25.08 25.60 34.95 27.63 22.58 38.37 25.21 30.01 33.62 21.16 24.34 20.90 20.29 24.08 30.02 32.90 29.30 — — —
Pfizer Inc. 14.64 13.82 15.62 17.19 18.14 17.36 15.05 15.62 16.20 16.11 16.34 16.88 16.63 16.98 15.88 15.52 17.37 17.41 16.13 15.88 — — —
Regeneron Pharmaceuticals Inc. 16.21 15.41 14.44 17.53 16.43 18.75 14.23 16.71 23.63 29.60 32.24 28.70 29.64 36.67 30.59 30.74 46.28 56.91 51.70 49.17 — — —
Vertex Pharmaceuticals Inc. 64.96 52.36 56.45 74.57 66.84 442.93 — 331.55 1,018.05 112.83 99.84 2,143.58 — — — — — — — — — — —
Zoetis Inc. 30.23 32.11 27.78 22.59 23.98 23.28 21.51 22.33 21.75 20.64 20.42 18.65 18.87 20.90 28.06 28.09 30.55 33.83 24.10 24.45 — — —

Based on: 10-Q (filing date: 2019-10-31), 10-Q (filing date: 2019-07-25), 10-Q (filing date: 2019-04-25), 10-K (filing date: 2019-02-25), 10-Q (filing date: 2018-10-25), 10-Q (filing date: 2018-07-26), 10-Q (filing date: 2018-04-26), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-26), 10-Q (filing date: 2017-07-27), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-21), 10-Q (filing date: 2016-10-27), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-04-28), 10-K (filing date: 2016-02-12), 10-Q (filing date: 2015-10-27), 10-Q (filing date: 2015-07-23), 10-Q (filing date: 2015-04-28), 10-K (filing date: 2015-02-13), 10-Q (filing date: 2014-10-24), 10-Q (filing date: 2014-07-24), 10-Q (filing date: 2014-04-29).

1 Data adjusted for splits and stock dividends.

2 Q3 2019 Calculation
Operating profit per share = (Operating incomeQ3 2019 + Operating incomeQ2 2019 + Operating incomeQ1 2019 + Operating incomeQ4 2018) ÷ No. shares of common stock outstanding
= (1,760,000,000 + 1,877,000,000 + 1,719,000,000 + 1,567,000,000) ÷ 1,629,284,798 = 4.25

3 Closing price as at the filing date of Bristol-Myers Squibb Co.’s Quarterly or Annual Report.

4 Q3 2019 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 57.37 ÷ 4.25 = 13.50

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. Bristol-Myers Squibb Co.’s P/OP ratio decreased from Q1 2019 to Q2 2019 but then increased from Q2 2019 to Q3 2019 not reaching Q1 2019 level.

Price to Sales (P/S)

Bristol-Myers Squibb Co., historical P/S calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
No. shares of common stock outstanding1 1,629,284,798 1,635,766,530 1,635,705,782 1,632,675,877 1,632,198,774 1,631,876,909 1,634,538,458 1,632,582,502 1,636,699,696 1,639,926,446 1,647,434,458 1,672,715,340 1,671,229,946 1,670,858,535 1,669,307,273 1,669,459,090 1,668,286,317 1,667,502,766 1,666,974,545 1,662,118,446 1,658,776,491 1,657,904,666 1,657,176,162
Selected Financial Data (US$)
Revenues (in millions) 6,007  6,273  5,920  5,973  5,691  5,704  5,193  5,449  5,254  5,144  4,929  5,243  4,922  4,871  4,391  4,287  4,069  4,163  4,041  4,258  3,921  3,889  3,811 
Sales per share2 14.84 14.58 14.24 13.82 13.50 13.24 12.87 12.73 12.57 12.34 12.12 11.61 11.05 10.54 10.13 9.92 9.91 9.82 9.66 9.55 0.00 0.00 0.00
Share price1, 3 57.37 45.40 45.64 50.65 49.21 57.92 52.04 63.87 60.95 54.24 55.67 54.78 51.96 74.66 72.26 60.20 66.80 68.24 64.54 60.04 53.63 49.46 49.32
Valuation Ratio
P/S ratio4 3.87 3.11 3.21 3.67 3.64 4.38 4.04 5.02 4.85 4.40 4.59 4.72 4.70 7.08 7.13 6.07 6.74 6.95 6.68 6.28 — — —
Benchmarks
P/S Ratio, Competitors5
Abbott Laboratories 4.72 4.98 4.52 4.37 3.98 3.84 3.57 3.84 3.77 3.62 3.40 3.70 2.73 3.21 2.74 2.78 3.28 3.67 3.40 3.53 — — —
AbbVie Inc. 3.69 2.96 3.56 3.58 4.06 4.60 5.37 6.67 5.50 4.25 4.07 3.84 3.79 4.38 4.25 3.83 4.78 5.41 5.09 4.90 — — —
Allergan PLC 3.70 3.34 2.95 2.93 3.32 3.91 3.12 3.40 3.77 5.28 5.43 5.65 5.47 7.11 5.59 7.81 7.22 7.83 9.13 5.79 — — —
Amgen Inc. 5.61 5.00 4.78 5.22 5.56 5.65 5.27 5.82 5.85 5.85 5.48 5.65 5.01 5.97 5.60 5.28 5.89 6.65 6.22 6.13 — — —
Biogen Inc. 3.57 3.16 3.15 4.87 4.81 5.83 4.39 5.96 5.64 5.11 5.28 4.98 5.65 5.51 5.60 5.49 5.83 6.85 9.33 9.46 — — —
Eli Lilly & Co. 4.67 4.67 4.80 5.15 4.62 4.34 3.85 3.71 4.11 4.16 4.18 4.18 3.95 4.44 4.13 4.02 4.59 4.78 4.07 4.03 — — —
Gilead Sciences Inc. 3.76 3.69 3.84 3.84 4.17 4.43 3.52 4.10 3.54 3.42 3.05 3.08 3.13 3.32 3.48 3.80 5.07 6.06 5.65 6.36 — — —
Johnson & Johnson 4.16 4.32 4.62 4.45 4.61 4.36 4.29 4.56 5.06 4.93 4.60 4.62 4.37 4.78 4.49 4.13 3.96 3.86 3.77 3.77 — — —
Merck & Co. Inc. 4.59 4.87 4.67 4.92 4.57 4.29 3.75 3.68 3.80 4.25 4.34 4.54 4.15 4.41 3.80 3.56 3.87 4.09 4.12 3.93 — — —
Pfizer Inc. 3.85 3.80 4.20 4.49 4.75 4.51 3.89 4.05 4.00 3.80 3.75 3.84 3.82 4.08 3.95 3.76 4.40 4.50 4.21 4.24 — — —
Regeneron Pharmaceuticals Inc. 4.79 4.56 5.11 6.62 6.08 6.92 5.20 5.92 8.09 9.56 9.27 7.86 7.61 9.82 8.95 9.38 15.41 17.74 15.80 14.62 — — —
Vertex Pharmaceuticals Inc. 13.89 13.34 13.54 15.54 14.96 17.14 16.47 16.42 16.47 18.23 14.60 12.51 11.33 15.62 15.73 20.38 40.39 54.65 51.27 47.41 — — —
Zoetis Inc. 9.37 9.57 8.35 7.03 7.92 7.88 7.10 7.18 6.40 5.85 5.83 5.31 4.95 5.21 4.87 4.42 4.70 5.01 4.76 4.82 — — —

Based on: 10-Q (filing date: 2019-10-31), 10-Q (filing date: 2019-07-25), 10-Q (filing date: 2019-04-25), 10-K (filing date: 2019-02-25), 10-Q (filing date: 2018-10-25), 10-Q (filing date: 2018-07-26), 10-Q (filing date: 2018-04-26), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-26), 10-Q (filing date: 2017-07-27), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-21), 10-Q (filing date: 2016-10-27), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-04-28), 10-K (filing date: 2016-02-12), 10-Q (filing date: 2015-10-27), 10-Q (filing date: 2015-07-23), 10-Q (filing date: 2015-04-28), 10-K (filing date: 2015-02-13), 10-Q (filing date: 2014-10-24), 10-Q (filing date: 2014-07-24), 10-Q (filing date: 2014-04-29).

1 Data adjusted for splits and stock dividends.

2 Q3 2019 Calculation
Sales per share = (RevenuesQ3 2019 + RevenuesQ2 2019 + RevenuesQ1 2019 + RevenuesQ4 2018) ÷ No. shares of common stock outstanding
= (6,007,000,000 + 6,273,000,000 + 5,920,000,000 + 5,973,000,000) ÷ 1,629,284,798 = 14.84

3 Closing price as at the filing date of Bristol-Myers Squibb Co.’s Quarterly or Annual Report.

4 Q3 2019 Calculation
P/S ratio = Share price ÷ Sales per share
= 57.37 ÷ 14.84 = 3.87

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. Bristol-Myers Squibb Co.’s P/S ratio decreased from Q1 2019 to Q2 2019 but then increased from Q2 2019 to Q3 2019 exceeding Q1 2019 level.

Price to Book Value (P/BV)

Bristol-Myers Squibb Co., historical P/BV calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
No. shares of common stock outstanding1 1,629,284,798 1,635,766,530 1,635,705,782 1,632,675,877 1,632,198,774 1,631,876,909 1,634,538,458 1,632,582,502 1,636,699,696 1,639,926,446 1,647,434,458 1,672,715,340 1,671,229,946 1,670,858,535 1,669,307,273 1,669,459,090 1,668,286,317 1,667,502,766 1,666,974,545 1,662,118,446 1,658,776,491 1,657,904,666 1,657,176,162
Selected Financial Data (US$)
Total Bristol-Myers Squibb Company shareholders’ equity (in millions) 17,648  16,049  15,218  14,031  13,640  12,317  12,793  11,741  14,783  14,699  14,416  16,177  15,613  14,918  14,386  14,266  15,079  15,123  15,546  14,852  15,143  15,327  15,473 
Book value per share (BVPS)2 10.83 9.81 9.30 8.59 8.36 7.55 7.83 7.19 9.03 8.96 8.75 9.67 9.34 8.93 8.62 8.55 9.04 9.07 9.33 8.94 9.13 9.24 9.34
Share price1, 3 57.37 45.40 45.64 50.65 49.21 57.92 52.04 63.87 60.95 54.24 55.67 54.78 51.96 74.66 72.26 60.20 66.80 68.24 64.54 60.04 53.63 49.46 49.32
Valuation Ratio
P/BV ratio4 5.30 4.63 4.91 5.89 5.89 7.67 6.65 8.88 6.75 6.05 6.36 5.66 5.56 8.36 8.38 7.04 7.39 7.52 6.92 6.72 5.87 5.35 5.28
Benchmarks
P/BV Ratio, Competitors5
Abbott Laboratories 4.65 4.86 4.49 4.38 3.94 3.72 3.23 3.40 2.95 2.71 2.42 3.76 2.72 3.20 2.70 2.68 3.19 3.27 3.17 3.32 2.87 2.66 2.48
AbbVie Inc. — — — — — — 44.74 36.95 22.43 18.89 21.33 21.24 14.80 19.21 21.77 22.17 21.56 20.64 75.48 56.09 21.09 15.99 17.69
Allergan PLC 1.00 0.88 0.75 0.71 0.76 0.89 0.69 0.73 0.82 1.06 1.07 1.08 0.82 1.28 1.15 1.54 1.53 1.74 1.66 2.67 2.25 5.86 3.77
Amgen Inc. 11.47 10.37 9.92 9.41 8.56 8.35 7.41 5.02 3.98 4.05 3.91 4.14 3.51 4.27 4.16 3.94 4.38 4.87 4.66 4.59 4.77 3.98 3.72
Biogen Inc. 3.63 3.44 3.15 5.03 4.63 6.13 3.94 5.80 5.19 5.16 5.30 4.70 5.32 5.43 5.93 6.31 5.83 5.61 8.10 8.49 7.00 8.34 7.96
Eli Lilly & Co. 31.28 39.03 46.37 12.87 8.58 8.96 6.18 7.33 6.20 6.49 6.43 6.33 5.28 6.25 5.55 5.51 5.94 6.39 5.35 5.14 4.13 3.94 3.60
Gilead Sciences Inc. 4.02 3.58 3.83 3.89 3.98 4.66 4.15 5.15 3.85 4.23 4.28 4.88 5.78 6.83 8.42 6.59 9.02 10.69 8.88 10.08 11.79 8.66 9.04
Johnson & Johnson 5.84 5.78 6.39 6.08 5.81 5.60 5.34 5.79 5.08 4.98 4.72 4.72 4.30 4.68 4.34 4.07 3.91 3.90 4.09 4.01 3.91 3.61 3.67
Merck & Co. Inc. 7.87 7.82 7.31 7.79 5.88 5.44 4.54 4.30 3.96 4.31 4.35 4.51 3.78 4.01 3.42 3.15 3.37 3.54 3.57 3.42 3.71 3.32 3.21
Pfizer Inc. 3.14 3.42 3.84 3.80 3.55 3.44 2.80 2.98 3.45 3.41 3.37 3.40 3.21 3.40 3.19 2.84 3.15 3.24 3.07 2.95 2.43 2.32 2.39
Regeneron Pharmaceuticals Inc. 3.48 3.38 3.74 5.07 4.92 5.97 4.80 5.66 7.37 9.07 9.49 8.58 8.02 11.19 10.54 10.53 17.80 18.04 16.29 16.22 14.84 14.22 12.83
Vertex Pharmaceuticals Inc. 9.57 9.09 9.36 10.68 14.56 16.73 16.56 20.14 21.11 23.25 19.64 18.42 18.42 24.79 21.23 22.38 33.24 38.35 31.53 25.60 24.41 18.06 13.13
Zoetis Inc. 21.53 24.00 21.31 18.74 21.38 22.36 19.72 21.52 16.49 17.11 17.96 17.46 15.25 18.64 20.16 19.72 18.42 20.48 17.82 17.61 14.76 12.91 14.30

Based on: 10-Q (filing date: 2019-10-31), 10-Q (filing date: 2019-07-25), 10-Q (filing date: 2019-04-25), 10-K (filing date: 2019-02-25), 10-Q (filing date: 2018-10-25), 10-Q (filing date: 2018-07-26), 10-Q (filing date: 2018-04-26), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-26), 10-Q (filing date: 2017-07-27), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-21), 10-Q (filing date: 2016-10-27), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-04-28), 10-K (filing date: 2016-02-12), 10-Q (filing date: 2015-10-27), 10-Q (filing date: 2015-07-23), 10-Q (filing date: 2015-04-28), 10-K (filing date: 2015-02-13), 10-Q (filing date: 2014-10-24), 10-Q (filing date: 2014-07-24), 10-Q (filing date: 2014-04-29).

1 Data adjusted for splits and stock dividends.

2 Q3 2019 Calculation
BVPS = Total Bristol-Myers Squibb Company shareholders’ equity ÷ No. shares of common stock outstanding
= 17,648,000,000 ÷ 1,629,284,798 = 10.83

3 Closing price as at the filing date of Bristol-Myers Squibb Co.’s Quarterly or Annual Report.

4 Q3 2019 Calculation
P/BV ratio = Share price ÷ BVPS
= 57.37 ÷ 10.83 = 5.30

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company’s required rate of return and its actual rate of return. Bristol-Myers Squibb Co.’s P/BV ratio decreased from Q1 2019 to Q2 2019 but then increased from Q2 2019 to Q3 2019 exceeding Q1 2019 level.